ABSCI CORPORATION - COMMON STOCK

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

16 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

11 Dec 2025 08:00:01 By Nasdaq GlobeNewswire

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

10 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

04 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

12 Nov 2025 16:05:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

29 Oct 2025 17:24:08 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

27 Oct 2025 08:00:01 By Nasdaq GlobeNewswire

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

15 Oct 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

11 Sep 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

25 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

20 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

12 Aug 2025 16:05:01 By Nasdaq GlobeNewswire

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

07 Aug 2025 02:00:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

30 Jul 2025 16:05:00 By Nasdaq GlobeNewswire

Absci Announces Pricing of Public Offering of Common Stock

24 Jul 2025 20:45:17 By Nasdaq GlobeNewswire

Absci Announces Proposed Public Offering of Common Stock

24 Jul 2025 16:54:49 By Nasdaq GlobeNewswire

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

07 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

20 May 2025 08:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

13 May 2025 16:05:00 By Nasdaq GlobeNewswire

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

13 May 2025 16:01:00 By Nasdaq GlobeNewswire